Golden Biotechnology Corp.   Report issue

For profit Phase 2
Founded: Taipei Taiwan (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2009
NCT01007656
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Golden Biotechnology Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

antroquinonol (10 trials)

Drugs in Other Trials (3)

antrodia camphorata (1 trial)

astragalus membranaceus (1 trial)

soybean (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 4